Sugi Predict

Sugi Predict / Compounds / SCHEMBL2177634

SCHEMBL2177634

SCHEMBL2177634

CC(C)[C@@H](C(=O)O)N1Cc2cc(-c3ccc(NC(=O)Nc4ccc(C#N)cc4)cc3)ccc2C1=O

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SDCBP O00560 6/20 0.46
▸ SDC2 P34741 6/20 0.46
▸ LMNA P02545 2/20 0.43
▸ TP53 P04637 1/20 0.43
▸ VHL P40337 1/20 0.41
▸ DGAT1 O75907 1/20 0.40
▸ MAPT P10636 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ CNR1 P21554 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ NLRP3 Q96P20 1/20 0.39
▸ SAE1 Q9UBE0 1/20 0.38
▸ UBA2 Q9UBT2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2177643 1.00 SDCBP (0.46) SDCBPSDC2LMNATP53VHL
SCHEMBL2179767 0.93 SDCBP (0.44) SDCBPSDC2LMNATP53VHL
SCHEMBL2181420 0.93 SDCBP (0.44) SDCBPSDC2LMNATP53VHL
SCHEMBL2178543 0.92 LMNA (0.43) SDCBPSDC2LMNATP53VHL
SCHEMBL2178255 0.92 LMNA (0.43) SDCBPSDC2LMNATP53VHL
SCHEMBL2178135 0.92 MEN1 (0.47) SDCBPSDC2LMNATP53MAPT
SCHEMBL2178453 0.92 MEN1 (0.47) SDCBPSDC2LMNATP53MAPT
SCHEMBL2181226 0.89 LMNA (0.51) SDCBPSDC2LMNATP53DGAT1
SCHEMBL2179718 0.89 LMNA (0.51) SDCBPSDC2LMNATP53DGAT1
SCHEMBL2177104 0.88 SDCBP (0.48) SDCBPSDC2LMNATP53DGAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 — — US claimed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 — — US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 — — EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 — — WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 — — US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 — — US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 — — EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT SDCBP 2373/4885SDC2 3855/4885LMNA 2193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.